Showing results (211-220 of 319) with videos related to

Sort By:
Pageof 32
Blood|March 27, 2013
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activityJunli Yan, Siok-Bian Ng, Jim Liang-Seah Tay, et al.
Leukemia & Lymphoma|November 11, 2014
Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotypeSiok-Bian Ng, Koichi Ohshima, Viknesvaran Selvarajan, et al.
International Journal of Antimicrobial Agents|May 12, 2018
Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropeniaAi Leng Khoo, Ying Jiao Zhao, Monica Teng, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Blood|January 16, 2009
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLJianbiao Zhou, Chonglei Bi, Jasinghe V Janakakumara, et al.
Haematologica|March 11, 2021
ZRSR1 co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cellsVikas Madan, Zeya Cao, Weoi Woon Teoh, et al.
Blood Advances|June 3, 2026
Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple MyelomaMinchuan Zhang, Wai Fook Leong, Jianxin Huo, et al.
Frontiers in Immunology|April 29, 2024
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphomaWendy W L Lee, Jing Quan Lim, Tiffany P L Tang, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
British Journal of Haematology|July 30, 2013
Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemiaJunli Yan, Nan Jiang, Gaofeng Huang, et al.
Pageof 32